Skip to main content

Changing Patterns of Asthma Medication use Related to U.S. Food and Drug Administration Long-Acting Beta2-agonist Regulation from 2005-2011

Basic Details
Date
Type
Publication
Medical Product
asthma medication
long-acting beta2 agonist (LABA)
Description

Safety concerns associated with long-acting β2-agonists (LABAs) have led to many US Food and Drug Administration (FDA) regulatory activities for this class of drugs. Little is known about the effect of these regulatory activities on use of LABA-containing agents or other asthma medications.

Materials

J Allergy Clin Immunol; Volume 137, Issue 3, Pages 710-717, DOI: http://dx.doi.org/10.1016/j.jaci.2015.09.057

Related Assessment(s)
Long-Acting Beta2-agonists (LABA) Policies and Drug Utilization Patterns
Author(s)

Melissa G. Butler PharmD, PhD, MPH, Esther H. Zhou MD, PhD, Fang Zhang PhD, Yu-te Wu PhD, Ann Chen Wu MD, MPH, Mark S. Levenson PhD, Pingsheng Wu PhD, Sally Seymour MD, Sengwee Toh ScD, Aarthi Iyer MPH, Solomon Iyasu MD, MPH, Meghan A. Baker MD, ScD

Corresponding Author

Meghan A. Baker, Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, 401 Park Drive, Suite 401 East, Boston, MA, 02215, USA. Email: meghan_baker@harvardpilgrim.org